[Click e-Stock] "Curexo Expected to See Growth in Medical Robotics Division"

On January 22, Kiwoom Securities projected that the profitability of Curexo's medical robotics division would improve.

Shin Minsu, a researcher at Kiwoom Securities, stated, "The knee joint surgical robot 'Cuvise Joint' accounts for 80% of sales in Curexo's surgical robotics division," adding, "The joint surgery robot business in India is positioned for additional growth this year."

He further explained, "We have resumed equipment shipments and responses following requests for reinstatement from our partner companies."

Shin noted, "The low profit margin is due to costs incurred in responding to regulations related to clinical trials and approvals in the United States and Europe," and analyzed, "In the second half of this year, profit margins are expected to improve through continued topline growth and cost reductions."

He introduced, "Certification under the European Union's Medical Device Regulation (MDR) is expected to be obtained within the first quarter of this year, and sales of joint surgery robots will begin within the year." He added, "Leveraging the open platform feature, the robots are compatible with multiple implant brands in regions such as Italy."

He continued, "Joint research is also underway," and emphasized, "After commercialization, we expect to generate sales synergy and record sales of 5 to 10 units in Europe this year."

Shin stated, "We expect to obtain approval from the U.S. Food and Drug Administration (FDA) for Cuvise Joint in the third quarter of this year."